Data as of Apr 15
| +3.24 / +9.94%|
The 5 analysts offering 12-month price forecasts for KYTHERA Biopharmaceuticals Inc have a median target of 56.00, with a high estimate of 68.00 and a low estimate of 44.00. The median estimate represents a +56.34% increase from the last price of 35.82.
The current consensus among 5 polled investment analysts is to Buy stock in KYTHERA Biopharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.